Responses
Other responses
Jump to comment:
- Published on: 13 February 2014
- Published on: 10 December 2013
- Published on: 13 February 2014Response to Dr Iannone's eLetterShow More
Dear Editor,
We thank Dr. Iannone et al for their comment on our recent study on drug survival on etanercept, infliximab and adalimumab in patients with RA.[1] They noted similarities between our findings and their previously published data[2] on 853 Italian patients starting TNF inhibitor treatment in 2003-2004 in terms of best drug survival on etanercept, similar 4- vs 5 -year drug survival for etanercept and infl...
Conflict of Interest:
None declared. - Published on: 10 December 2013Drug survival on TNF inhibitors: 2003-2004 data from Italian national register (GISEA Register)Show More
Dear Editor,
We read with interest the findings of the paper by Neovius et al recently published on Annals of the Rheumatic Diseases 1 who retrospectively studied the drug survival on TNF-alpha blockers in patients with rheumatoid arthritis (RA) in real life settings. The primary endpoint of their analysis was to assess the drug discontinuation rates in RA patients starting a first ever TNF-alpha inhibitor, and to...
Conflict of Interest:
None declared.